Resolving controversies in the management and the role of autoimmunity in subclinical hypothyroidism: a prospective evaluation of risks and of therapy impact
Description: <p><strong>Background</strong><br>Subclinical thyroid dysfunction (SCTD) is a mild thyroid problem that often affects people aged 65 and older, with about 10-15% older adults experiencing it. Some doctors have worried that even mild changes in thyroid function could raise the risk of heart attacks and strokes or worsen other health issues. Previous studies, including our own large trial (TRUST), found that thyroid hormone treatment (levothyroxine, or LT4) did not improve common symptoms of hypothyroidism in older adults. However, it remains unclear if taking LT4 could lower the risk of heart disease, or if certain groups—like younger patients or those with high thyroid antibodies—might benefit.</p><p><strong>What We Did</strong><br>Our research included two main parts:</p><ul> <li>We looked at specific subgroups (people younger than 65, those with heart disease, higher hormone levels, or specific antibodies) to see if mild thyroid problems had bigger impact for them.</li> <li>We used data from two large medical trials to find out whether people with positive thyroid antibodies actually benefited from LT4 treatment.</li></ul><p><strong>Why This Research Matters</strong><br>Our project is the largest and most complete study of SCTD ever done, combining information from over 167,000 people in 29 countries and two major trials in older adults. Despite previous associations in smaller studies, key findings include:</p><ul> <li>There was no increased risk of diabetes or major heart risk differences for people with mild thyroid problems compared to those with normal thyroid levels.</li> <li>Using thyroid antibody levels to decide which older adults should get LT4 treatment was not supported by our large clinical trials.</li> <li>Taking LT4 did not improve muscle strength, body composition, blood counts, quality of life, or patient satisfaction—including for those with thyroid antibodies.</li> <li><em>Possible high-risk group spotted</em>: adults with high TSH (≥7.0 mIU/L) and a history of heart failure may need special attention.</li> <li>We identified thyroid hormone ranges that appear most closely associated with better heart and survival outcomes.</li></ul><p><strong>Looking Ahead</strong><br>Most older adults with mild thyroid dysfunction do not benefit from routine LT4 treatment. Our results suggest that treatment should be more targeted and personalized to high-risk people. This work helps guide doctors worldwide: our findings are now included in both European and U.S. medical guidelines, shaping the future of thyroid care. Our studies answered several important questions, and will help to avoid unnecessary treatments, and highlighted groups who might still be at risk—with the final aim to provide safer, more effective care for everyone.</p><br>
Amount: CHF 921,700
Funding type: research
Funder scheme: Project funding
Start date: 2021-07-01
End date: 2025-06-30
Investigator: Rodondi, Nicolas (lead)
Institutions: University of Bern, University of Berne – BE
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Funded outputs count: 15
Funder award ID: 200606
OpenAlex ID: G8502526346
